Neurocrine Biosciences Elects New Directors, Amends Bylaws
Ticker: NBIX · Form: 8-K · Filed: 2024-05-28T00:00:00.000Z
Sentiment: neutral
Topics: governance, board-of-directors, bylaws
Related Tickers: NBI
TL;DR
Board shakeup at NBI: two new directors in, bylaws updated.
AI Summary
Neurocrine Biosciences, Inc. announced on May 24, 2024, a change in its board of directors, with the election of two new directors, Dr. Richard A. F. Clark and Ms. Sarah L. Kelly. The company also reported on compensatory arrangements for its named executive officers and filed amendments to its bylaws. This filing does not contain specific financial figures or new product updates.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance. Amendments to bylaws can affect operational procedures and shareholder rights.
Risk Assessment
Risk Level: low — The filing primarily concerns corporate governance changes and does not involve significant financial transactions or operational shifts that would inherently increase risk.
Key Players & Entities
- Neurocrine Biosciences, Inc. (company) — Registrant
- Dr. Richard A. F. Clark (person) — Newly elected director
- Ms. Sarah L. Kelly (person) — Newly elected director
- May 24, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors elected to Neurocrine Biosciences' board?
Dr. Richard A. F. Clark and Ms. Sarah L. Kelly were elected as new directors.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated May 24, 2024.
What other items are covered in this 8-K filing besides director changes?
The filing also covers amendments to articles of incorporation or bylaws, and compensatory arrangements of certain officers.
What is Neurocrine Biosciences' state of incorporation?
Neurocrine Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Neurocrine Biosciences?
The principal executive offices are located at 6027 Edgewood Bend Court, San Diego, CA 92130.
Filing Stats: 717 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-05-28 16:18:30
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select
Filing Documents
- d836271d8k.htm (8-K) — 27KB
- d836271dex31.htm (EX-3.1) — 2KB
- g836271g0528074534164.jpg (GRAPHIC) — 9KB
- 0001193125-24-148107.txt ( ) — 174KB
- nbix-20240524.xsd (EX-101.SCH) — 3KB
- nbix-20240524_lab.xml (EX-101.LAB) — 18KB
- nbix-20240524_pre.xml (EX-101.PRE) — 11KB
- d836271d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit Description 3.1 Certificate of Amendment of Bylaws 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 28, 2024 NEUROCRINE BIOSCIENCES, INC. /s/ Darin M. Lippoldt Darin M. Lippoldt Chief Legal Officer